Malignant Hepatobiliary Neoplasm Clinical Trial
Official title:
Endoscopic Ultrasonography-Guided Biliary Drainage Versus Percutaneous Trans-hepatic Biliary Drainage for Malignant Biliary Obstruction After Failed Endoscopic Retrograde Cholangio-pancreaticography
Endoscopic ultrasonography is a widely accepted modality for the diagnosis of
gastrointestinal and pancreatic-biliary diseases.
Endoscopic ultrasonography-guided biliary drainage has attracted attention as an alternative
procedure to percutaneous trans-hepatic biliary drainage, with a technical success between
75%-100% and with low complication rate. Other important advantage of endoscopic
ultrasonography-guided biliary drainage compared with external percutaneous trans-hepatic
biliary drainage is better quality of life due to the internal placement of the stent.
If endoscopic retrograde cholangio-pancreaticography fails to achieve biliary drainage, more
invasive options are usually considered. These include percutaneous trans-hepatic biliary
drainage and surgical intervention but they have been associated with a higher risk of
complications and prolonged hospital stay.
Some disadvantages with the percutaneous approach include the need to traverse the liver, a
decreased quality of life due to the presence of external drainage and a significant
morbidity and mortality, 7% and 5% respectively.
The external drainage of percutaneous trans-hepatic biliary drainage may add to the
patient's burden owing to the cosmetic problem, skin inflammation or pain, or bile leakage,
compromising the quality of life. From this point, the internal drainage of endoscopic
ultrasonography-guided biliary drainage eliminates several issues.
Endoscopic ultrasonography-guided biliary drainage using a metal stent, particularly a
lumen-apposing metal stent, can also be performed in patients with a large amount of
ascites, which is often contraindicated in percutaneous trans-hepatic biliary drainage.
Endoscopic ultrasonography-guided biliary drainage performed in the same session of the
failed endoscopic retrograde cholangio-pancreaticography, in the same room and under the
same sedation.
On the other hand, the endoscopic ultrasonography-guided biliary drainage, has major
limitation due to fewer cases reported till date and lack of long term data. Because of, the
technical difficulty encountered during re-intervention and problem of stent migration, the
expertise needed for such procedure is a major limitation of the techniques.
Furthermore, comparative studies of endoscopic ultrasonography-guided biliary drainage
versus percutaneous trans-hepatic biliary drainage are required to select the optimal
candidates and to best evaluate the technical and treatment outcomes also in terms of
quality of life and costs. Recently, Endoscopic ultrasonography-guided biliary drainage has
been introduced as an alternative for patients who had failed endoscopic retrograde
cholangio-pancreaticography.
Indications for endoscopic ultrasonography-guided biliary drainage:
1. Failed conventional endoscopic retrograde cholangio-pancreaticography.
2. Altered anatomy
3. Tumor preventing access into the biliary tree
4. Prior surgical procedure
5. Biliary sphincter stenosis
6. Contra-indication to percutaneous access
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02916199 -
Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method
|
N/A | |
Completed |
NCT05068739 -
Needle Knife Fistulotomy Versus Partial Ampullary Endoscopic Mucosal Resection for Difficult Biliary Cannulation
|
N/A | |
Recruiting |
NCT06053333 -
Social Determinants of Health in Hepatobiliary Cancer Patients
|
||
Recruiting |
NCT03857958 -
Metal Versus Plastic Stent in Malignant Hilar Biliary Obstruction
|
N/A | |
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Completed |
NCT02265341 -
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
|
Phase 2 | |
Recruiting |
NCT04704661 -
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
|
Phase 1 | |
Recruiting |
NCT05334069 -
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
|